Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479125 · ClinicalTrials.gov registry record
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
A clinical trial, sponsored by Conatus Pharmaceuticals.
- Terminated
- Registry status
- 40
- Enrollment target
NCT03479125: Clinical Trial study, sponsored by Conatus Pharmaceuticals.
NCT03479125 is a clinical trial that was terminated before completion, run by Conatus Pharmaceuticals. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03479125 was terminated before completion, sponsored by Conatus Pharmaceuticals.
- TERMINATED
- Registry status
- 40 participants
- Enrollment target
Study Summary
A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
Primary Outcome
To estimate the adjusted event rate for hepatocellular carcinoma in subjects with or without cirrhosis previously treated with emricasan or placebo.
Interventions
- DIAGNOSTIC_TEST Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2019-09-30 |
Why NCT03479125 stopped before completion
NCT03479125 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ultrasound is the first listed.
NCT03479125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03479125 about?
NCT03479125 is a clinical study titled "Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo". A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
What is the current status of trial NCT03479125?
This trial is currently terminated. The enrollment target is 40 participants. The study started on 2018-02-27. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03479125?
The interventions under investigation include: Ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03479125?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI